Q3 2026 Aarti Drugs Ltd Earnings Call Transcript
Key Points
- Aarti Drugs Ltd (BOM:524348) reported a 7% volume growth in its standalone business segment year-on-year.
- Export markets, particularly formulations, emerged as a key growth driver, contributing positively to margins.
- The Sayakha facility, operational since September 2025, achieved 30% utilization in its first quarter and is expected to reach 50% by March-April 2026.
- The company is progressing with backward integration, aiming for self-reliance in critical intermediates for its antidiabetic portfolio.
- Formulations business showed encouraging traction, especially in export markets, aligning with the strategy of moving towards higher-value offerings.
- Utilization levels remained low due to weaker antibiotic demand, impacting overall performance and operating leverage.
- Delays in shipments from China disrupted supply chains, extending lead times and adding cost pressures.
- A voluntary shutdown for refurbishment ahead of a European audit temporarily constrained production.
- New greenfield facilities operated below optimal utilization, putting pressure on profitability.
- The salicylic acid facility's production was lower than expected, affecting overall utilization.
Ladies and gentlemen, good day, and welcome to Q3 and nine months FY26 earnings conference call of Aarti Drugs Limited. (Operator Instructions)
Before we begin, a brief disclaimer. This call may contain forward-looking statements about the company, which are based on the beliefs, opinions and expectations of the company as on date of this call. These statements are not guarantee of future performance, and it may involve risks and uncertainties that are difficult to predict. I now hand over the conference to Mr. Adhish Patil, COO and CFO from Aarti Drugs Limited. Thank you, and over to you, sir.
Thank you. And good morning to all our stakeholders. We appreciate your participation in Aarti Drugs Q3 and nine months FY26 Earnings Conference Call. Joining me today are Mr. Harshit Savla, Joint Managing Director; Mr. Harit Shah, Whole-Time Director; Mr. Vishwa Savla, Managing Director, Pinnacle Life Sciences, along with our Investor Relations adviser, SGA.
We trust that you had the opportunity
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
